Table 3. Meta-analysis results of the associations of increased TrkB expression with clinicopathological parameters.

Clinicopathological parameter	Ref	Overall OR (95% CI)	P-value	Heterogeneity test (Q, I2, P-value)
Gender (male vs female)	[16–22, 24, 26]	0.907 (0.703–1.169)	0.451	8.52, 6.1%, 0.384
Differentiation (poor VS well)	[16–22, 24, 26]	0.867 (0.524–1.435)	0.451	25.11, 68.1%, 0.3677
Tumor size (T3–4 vs T1–2)	[16–18, 20–22, 24, 26]	1.960 (1.473–2.608)	0.000	5.83, 0.0%, 0.559
Lymph node metastasis (yes vs no)	[16–22, 24, 26]	1.927 (1.499–2.477)	0.000	7.51, 0.0%, 0.483
Distant metastasis (yes vs no)	[16–21]	2.755 (1.781–4.260)	0.000	4.70, 0.0%, 0.453
Clinical stage (III-IV vs I-II)	[16–17, 19, 21–22, 24, 26]	1.775 (1.159–2.716)	0.008	9.52, 37.0%, 0.146